Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Tao Jiang(Tongji University), Shengxiang Ren(Tongji University), Luonan Chen(Shanghai Jiao Tong University), Helong Zhang(Shanghai International Studies University), Caicun Zhou(Tongji University), Yanqiu Zhao(Henan Cancer Hospital), Yanjun Xu(Guangzhou Center for Disease Control and Prevention), Jianying Zhou(First Affiliated Hospital Zhejiang University), Renhua Guo(Sun Yat-sen University), Sheng Yao(BioReliance (United States)), Jiarui Wu(Beijing University of Chinese Medicine), Yongqian Shu(Jiangsu Province Hospital), Yalei Zhang(State Key Laboratory of Pollution Control and Resource Reuse), Jie Zhang(Hebei University of Chinese Medicine), Ningqiang Ma(Air Force Medical University), Linhong Deng(Changzhou University), Zhang Bao(First Affiliated Hospital Zhejiang University), Yun Fan(Zhejiang Cancer Hospital), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Hong Wang(Qingdao University), Guanghui Gao(Tongji University), Xiaoqing Liu(Chinese PLA General Hospital), Hui Feng(Boston University), Xiaoqian Mu(Henan Cancer Hospital), Pingyang Wang(Center for Excellence in Molecular Cell Science)
Cited by 94
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k